SCHEMBL3879252

SCHEMBL3879252

O=C(Nc1n[nH]c2cc(C(=O)O)oc12)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.45
CDK2 P24941 2/20 0.44
CDC7 O00311 1/20 0.44
DAPK3 O43293 1/20 0.44
ROCK2 O75116 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
FLT3 P36888 1/20 0.44
CSNK1A1 P48729 1/20 0.44
CDK8 P49336 1/20 0.44
CLK2 P49760 1/20 0.44
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
PRKX P51817 1/20 0.44
JAK3 P52333 1/20 0.44
CDK5 Q00535 1/20 0.44
MAP4K2 Q12851 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083540 0.89 FGFR1 (0.50) GPR35CDK2CDC7DAPK3ROCK2
SCHEMBL4092896 0.88 HDAC6 (0.51) GPR35CDK2CDC7DAPK3ROCK2
SCHEMBL4088257 0.87 AURKA (0.47) CDK2CDC7DAPK3ROCK2PRKD3
SCHEMBL4088594 0.85 GPR35 (0.55) GPR35CDK2CDK7CCNA2CCNA1
SCHEMBL4081310 0.85 GPR35 (0.52) GPR35CDK2CDC7DAPK3ROCK2
SCHEMBL4082126 0.84 HDAC6 (0.48) GPR35PIM1NPC1RAB9AHDAC6
SCHEMBL4081022 0.84 FLT3 (0.50) GPR35FLT3NPC1RAB9AHDAC6
SCHEMBL4695374 0.82 HDAC6 (0.41) CDK2CDC7DAPK3ROCK2PRKD3
SCHEMBL4088609 0.82 AURKA (0.49) CDK2CDC7DAPK3ROCK2PRKD3
SCHEMBL4088586 0.82 KCNK3 (0.42) GPR35RAB9AHDAC6KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058315-A1 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors Nerviano Medical Sciences S.r.l. (IT) 2009-05-13 EP claimed
US-7485661-B2 Heterobicyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-02-03 US claimed
EP-1534716-B1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-04-23 EP claimed
EP-2058315-A1 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors Nerviano Medical Sciences S.r.l. (IT) 2009-05-13 EP disclosed
US-7485661-B2 Heterobicyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-02-03 US disclosed
EP-1534716-B1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-04-23 EP disclosed
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2006-07-20 US disclosed
EP-1534716-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2005-06-01 EP disclosed
WO-2004007504-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors MAP2K2, MAP3K15, MAP3K5 GPR35 1563/4885CDK2 22/4885CDC7 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.